» Articles » PMID: 27568655

Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore Versus Magnetic Resonance Imaging-transrectal Ultrasound Fusion Versus Cognitive Registration. Is There a Preferred...

Overview
Journal Eur Urol
Specialty Urology
Date 2016 Aug 30
PMID 27568655
Citations 146
Authors
Affiliations
Soon will be listed here.
Abstract

Context: The introduction of magnetic resonance imaging-guided biopsies (MRI-GB) has changed the paradigm concerning prostate biopsies. Three techniques of MRI-GB are available: (1) in-bore MRI target biopsy (MRI-TB), (2) MRI-transrectal ultrasound fusion (FUS-TB), and (3) cognitive registration (COG-TB).

Objective: To evaluate whether MRI-GB has increased detection rates of (clinically significant) prostate cancer (PCa) compared with transrectal ultrasound-guided biopsy (TRUS-GB) in patients at risk for PCa, and which technique of MRI-GB has the highest detection rate of (clinically significant) PCa.

Evidence Acquisition: We performed a literature search in PubMed, Embase, and CENTRAL databases. Studies were evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 checklist and START recommendations. The initial search identified 2562 studies and 43 were included in the meta-analysis.

Evidence Synthesis: Among the included studies 11 used MRI-TB, 17 used FUS-TB, 11 used COG-TB, and four used a combination of techniques. In 34 studies concurrent TRUS-GB was performed. There was no significant difference between MRI-GB (all techniques combined) and TRUS-GB for overall PCa detection (relative risk [RR] 0.97 [0.90-1.07]). MRI-GB had higher detection rates of clinically significant PCa (csPCa) compared with TRUS-GB (RR 1.16 [1.02-1.32]), and a lower yield of insignificant PCa (RR 0.47 [0.35-0.63]). There was a significant advantage (p = 0.02) of MRI-TB compared with COG-TB for overall PCa detection. For overall PCa detection there was no significant advantage of MRI-TB compared with FUS-TB (p=0.13), and neither for FUS-TB compared with COG-TB (p=0.11). For csPCa detection there was no significant advantage of any one technique of MRI-GB. The impact of lesion characteristics such as size and localisation could not be assessed.

Conclusions: MRI-GB had similar overall PCa detection rates compared with TRUS-GB, increased rates of csPCa, and decreased rates of insignificant PCa. MRI-TB has a superior overall PCa detection compared with COG-TB. FUS-TB and MRI-TB appear to have similar detection rates. Head-to-head comparisons of MRI-GB techniques are limited and are needed to confirm our findings.

Patient Summary: Our review shows that magnetic resonance imaging-guided biopsy detects more clinically significant prostate cancer (PCa) and less insignificant PCa compared with systematic biopsy in men at risk for PCa.

Citing Articles

Identifying Optimal Prostate Biopsy Strategy for the Detection Rate of Clinically Significant Prostate Cancer: A Systematic Review and Meta-Analysis of Randomised Controlled Trials (RCTs) in Biopsy-Naïve Population.

Aloufi W, Al Mopti A, Al-Tawil A, Huang Z, Nabi G Cancers (Basel). 2025; 17(3).

PMID: 39941825 PMC: 11816062. DOI: 10.3390/cancers17030458.


Clinical feasibility of MRI-guided in-bore prostate biopsies at 0.55T.

Kaur T, Jiang Y, Seiberlich N, Hussain H, Wells S, Wei J Abdom Radiol (NY). 2025; .

PMID: 39794536 DOI: 10.1007/s00261-024-04783-x.


Integrated SERS-Microfluidic Sensor Based on Nano-Micro Hierarchical Cactus-like Array Substrates for the Early Diagnosis of Prostate Cancer.

Jia H, Meng W, Gao R, Wang Y, Zhan C, Yu Y Biosensors (Basel). 2024; 14(12).

PMID: 39727845 PMC: 11674406. DOI: 10.3390/bios14120579.


Factors influencing urinary retention following freehand transperineal prostate biopsy: Insights from a tertiary care center study.

Agrawal S, Patil V, Prasad V, Menon A, Pooleri G Indian J Urol. 2024; 40(4):229-234.

PMID: 39555426 PMC: 11567580. DOI: 10.4103/iju.iju_36_24.


Comparison of MRI artificial intelligence-guided cognitive fusion-targeted biopsy versus routine cognitive fusion-targeted prostate biopsy in prostate cancer diagnosis: a randomized controlled trial.

Deng R, Liu Y, Wang K, Ruan M, Li D, Wu J BMC Med. 2024; 22(1):530.

PMID: 39533250 PMC: 11559106. DOI: 10.1186/s12916-024-03742-z.